A Phase IIIb, Multicentre, Interventional, Randomised, Placebo‐Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G‐PLUS)
Dermatologic Therapy · 2023-01 · 2023 (1)
DOI: 10.1155/2023/9967747 ↗Abstract
Introduction . Despite the availability of effective biologic therapies for psoriasis, there is no gold‐standard treatment for nonpustular palmoplantar psoriasis (ppPsO). Methods . G‐PLUS, a phase IIIb, double‐blind, placebo‐controlled, multicentre clinical trial, randomised adults with moderate‐to‐severe nonpustular ppPsO and limited plaque psoriasis (Psoriasis Area and Severity Index (PASI) ≥3 but
EUVIMED